Kiniksa Pharmaceuticals, Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.1M
Doctors Paid
15,654
Transactions
48,415
2024 Total
$2.7M
Payment Breakdown by Category
Research$8.1M (72.8%)
Food & Beverage$961,786 (8.7%)
Royalty/License$215,751 (1.9%)
Consulting$173,702 (1.6%)
Travel$169,537 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.1M | 5,874 | 72.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 388 | 9.1% |
| Food and Beverage | $961,786 | 41,279 | 8.7% |
| Space rental or facility fees (teaching hospital only) | $262,070 | 45 | 2.4% |
| Royalty or License | $215,751 | 24 | 1.9% |
| Consulting Fee | $173,702 | 96 | 1.6% |
| Travel and Lodging | $169,537 | 630 | 1.5% |
| Honoraria | $142,180 | 54 | 1.3% |
| Grant | $45,900 | 12 | 0.4% |
| Education | $24,770 | 12 | 0.2% |
| Charitable Contribution | $10,000 | 1 | 0.1% |
Payments by Type
Research
$8.1M
5,874 transactions
General
$3.0M
42,541 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | $2.9M | 1 | 2,039 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor | $2.1M | 0 | 3,354 |
| Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study with Open-Label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects with Recurrent Pericarditis (RHAPSODY) | $1.6M | 1 | 227 |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation | $975,597 | 2 | 63 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease | $186,030 | 0 | 104 |
| PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY WITH OPEN-LABEL EXTENSION, TO ASSESS THE EFFICACY AND SAFETY OF RILONACEPT TREATMENT IN SUBJECTS WITH RECURRENT PERICARDITIS (RHAPSODY) | $151,016 | 0 | 53 |
| An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis | $127,922 | 0 | 1 |
| A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis | $61,041 | 5 | 25 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation | $18,923 | 0 | 2 |
| A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of mavrilimumab in giant cell arteritis | $10,393 | 1 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Robert Biederman, Md, MD | Cardiovascular Disease | Charleston, SC | $141,545 | $0 |
| Dr. John Ryan, Mbbchbao, MBBCHBAO | Cardiovascular Disease | Salt Lake City, UT | $141,269 | $0 |
| Dr. Antonio Abbate, M.d, M.D | Cardiovascular Disease | Charlottesville, VA | $77,300 | $0 |
| John Isaac, M.d, M.D | Interventional Cardiology | Houston, TX | $75,741 | $0 |
| Dr. David Homan, M.d, M.D | Cardiovascular Disease | Opelousas, LA | $72,329 | $0 |
| Dr. Ajit Raisinghani, M.d, M.D | Cardiovascular Disease | San Diego, CA | $58,386 | $0 |
| Dr. Krishnaswami Vijayaraghavan, M.d, M.D | Cardiovascular Disease | Scottsdale, AZ | $53,351 | $0 |
| Dr. Dipan Shah, M.d, M.D | Cardiovascular Disease | Houston, TX | $52,267 | $0 |
| Dr. Norman Lepor, M.d, M.D | Specialist | Beverly Hills, CA | $50,829 | $0 |
| Petros Efthimiou, Md, MD | Rheumatology | New York, NY | $47,812 | $0 |
| Dor Lotan, Md, MD | Cardiovascular Disease | New York, NY | $47,061 | $0 |
| Dr. Deepak Talreja, Md, MD | Cardiovascular Disease | Virginia Beach, VA | $40,920 | $0 |
| Amin Sabet, M.d, M.D | Cardiovascular Disease | Fresno, CA | $36,064 | $0 |
| Dr. Rigved Tadwalkar, M.d., M.s, M.D., M.S | Internal Medicine | Santa Monica, CA | $34,967 | $0 |
| Anna Imperato, M.d, M.D | Internal Medicine | Manhasset, NY | $28,324 | $0 |
| Mihir Barvalia, Md, MD | Cardiovascular Disease | El Cajon, CA | $27,848 | $0 |
| Dr. Jimmy Kerrigan, Md, MD | Cardiovascular Disease | Nashville, TN | $26,519 | $0 |
| Timothy Henry, Md, MD | Cardiovascular Disease | Cincinnati, OH | $25,844 | $0 |
| Dr. Arif Albulushi, Md, MD | Advanced Heart Failure and Transplant Cardiology | Bellevue, NE | $25,398 | $0 |
| Dr. Andrew Ertel, M.d, M.D | Cardiovascular Disease | York, PA | $24,328 | $0 |
| Dr. Dhanunjaya Lakkireddy, Md, MD | Cardiovascular Disease | Kansas City, KS | $23,264 | $0 |
| Dr. Chad Link, Do, DO | Cardiovascular Disease | Lansing, MI | $20,240 | $0 |
| Dr. Sushil Luis, Mbbs, MBBS | Cardiovascular Disease | Rochester, MN | $20,199 | $0 |
| Allan Klein, Md, MD | Cardiovascular Disease | Cleveland, OH | $19,257 | $0 |
| Michael Portman | Pediatric Cardiology | Seattle, WA | $19,156 | $0 |
About Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. has made $11.1M in payments to 15,654 healthcare providers, recorded across 48,415 transactions in the CMS Open Payments database. In 2024, the company paid $2.7M. The top product by payment volume is Arcalyst ($3.1M).
Payments were distributed across 121 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($1.3M to 4,498 doctors).
Payment categories include: Food & Beverage ($961,786), Consulting ($173,702), Research ($8.1M), Travel & Lodging ($169,537), Royalties ($215,751).
Kiniksa Pharmaceuticals, Ltd. is associated with 1 products in the CMS Open Payments database.